Search 

Biovotion AG is a Swiss based medical device company, providing solutions for continuous, non-invasive physiological monitoring. The Biovotion Vital Sign Monitoring (VSM) platform is a mobile, standalone wearable monitor of vital sign parameters, supported by integrated cloud services for data exchange and analysis. It is directed towards patients with chronic conditions featuring Biovotion’s patient-friendly, wearable monitoring concept.

The company holds internationally recognised know how, paired with an extensive IP portfolio in a number of fields, relevant to provide sensor technology and device development for continuous and non-invasive physiological monitoring, embedded into mHealth environments.

Targeting toxic oligomers in misfolded protein diseases is the basis for Crossbeta’s stable oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer´s, Parkinson’s, Huntington and Diabetes Type 2.

In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50%  neutralizing effect on oligomer-induced neurotoxicity.

Stable oligomers can also be used as reference in biomarker assays.

Enterome is developing diagnostic products based on metagenomics of the human intestinal microbiota in patients with metabolic and inflammatory bowel diseases.

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.

Oryzon is a biomarker discovery company with a dual therapeutic pipeline in oncology and neurodegeneration.   Founded in 2000, and venture backed from 2002, Oryzon has a strong focus in EPIGENETIC TARGETS with a special emphasis in Histone Lysine Demethylases being a global leader on Lysine Specific Demethylase1. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration. Two recent papers in NatureMedicine and CancerCELL stablished proof of concept data that support the use of LSD1 inhibitors in acute myeloid leukemia. Oryzon has two preclinical programs with different preclinical candidates LSD1i, one in leukemia and the other in Huntington disease. Phase I/IIa studies are expected to start in early 2013.

In Oncology, we also develop new non invasive early diagnostics tools. Our first product GynEC®-DX consists on a new set of markers for triage in endometrial cancer from uterine aspirates.

Oxford Cancer Biomarkers (OCB) is a newly launched company developing tests that predict which cancer patients will respond favorably to existing and emerging cancer drugs allowing treatment to be tailored to individual patients.

The company, which is a spin out from Oxford University, has a patent-protected and validated platform for discovering proteins that are novel chemosensitivity markers for specific drugs.

OCB is developing its biomarkers tests both independently and in partnership with pharma and biotech companies.

Setting the company apart from the crowd, OCB has already implemented a strategic relationship with Quintiles that provides a route for accelerating its novel biomarkers into clinical trials, overcoming the inertia that can sometimes hamper the companion biomarker business model.

The company has secured initial funding via a $5 million equity investment from Quintiles.

OCB's management team, led by Nick McCooke, former CEO of Solexa (the pioneer of next gen sequencing) and Pronota (protein biomarker diagnostic development), includes David Kerr, Professor of Cancer Medicine at the University of Oxford and a recent President of the European Society of Medical Oncology, and Nick La Thangue, Professor of Cancer Biology at the University of Oxford.

The PROTAGEN GROUP is a leading provider of solutions for the

Pharmaceutical and Biotech industries, supporting drug development towards

personalized medicines and GMP compliant protein characterization services

of outstanding quality.

The PROTAGEN GROUP consists of PROTAGEN AG with a clear focus on

diagnostics, and PROTAGEN Protein Services GmbH (PPS) providing GMP

compliant protein analysis.

PROTAGEN AG has developed the proprietary UNIarray® platform to support

patient stratification and the development of Companion Diagnostics (CDx)

using the diagnostic power of autoantibody signatures in blood. We combine

our outstanding know-how in biostatistics and expertise in Protein arrays and

Luminex technology for the development of novel diagnostic assays. Our R&D

focus is on chronic diseases, e.g. neurodegenerative disorders, endometriosis,

autoimmune diseases such as Rheumatoid Arthritis, Systemic Lupus

Erythematosus and Multiple Sclerosis as well as selected cancer indications,

e.g. Prostate-, Breast-, Ovarian-, Colon- and Pancreatic Cancer.

PROTAGEN Protein Services GmbH (PPS)

is a reliable partner for GMP compliant characterization of biotherapeutics

(NBEs) and biosimilar comparability, including stability and release testing.

PPS combines unique expertise in bioinformatics for protein mass spectrometry

with a long track record in protein chemistry and protein analytics in order to

provide the best quality available. In addition, we provide customer support for

all relevant regulatory issues to match with current regulatory requirements

(FDA, EMA, KFDA) for protein drugs.